Sign inJoin waitlistJoin the waitlist

Parminder Singh

Associate Professor of Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Medical Oncology
2005–2007
Internal Medicine
2002–2005
Doctor of Medicine
1998–2002

Research

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With…
Journal of Clinical Oncology · 2018 · 522 citations
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
New England Journal of Medicine · 2025 · 134 citations
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2023 · 109 citations

Alan Bryce
14 papers
Irbaz Riaz
12 papers · 12 as a fellow
Neeraj Agarwal
8 papers
GS
Guru Sonpavde
7 papers
HM
Hassan Murad
7 papers
Daniel Childs
6 papers
Jacob Orme
6 papers
Oliver Sartor
6 papers
Sumanta Pal
6 papers
Thai Ho
6 papers
Yousef Zakharia
6 papers
Bradley McGregor
5 papers

Clinical trials

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2019–2027
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Principal investigator · Completed · Phase 2
Mayo Clinic
2018–2020
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Site PI · Recruiting
Mayo Clinic
2024–2027
A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies
Site PI · Unknown · Phase 1
Athenex, Inc.
2017–2020